MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect.

Automated summary

COVID-19 vaccines may increase the risk of immune-mediated diseases, as shown in a case of ANCA-associated vasculitis following vaccination with the BNT162b2 vaccine. The causal relationship between the vaccine and vasculitis is uncertain, but environmental and genetic factors may have played a role in the development of the disease, with the vaccine potentially triggering a chain reaction.